COINS and Biotech: The Deal Structure May Matter More Than the License
Treasury’s proposed COINS rules may leave traditional pharma licensing outside core restrictions while creating new questions for equity, joint-venture and NewCo deals.
AI + Healthcare, Part 3: AI’s Next Phase Is About Control, Not Speed
AI’s next phase will be defined not only by technical speed, but by governance, data protection, accountability and measurable value.